WO2004092206A1 - 新規ペプチドおよび免疫賦活剤、機能性食品ならびに機能性食品の製造方法 - Google Patents
新規ペプチドおよび免疫賦活剤、機能性食品ならびに機能性食品の製造方法 Download PDFInfo
- Publication number
- WO2004092206A1 WO2004092206A1 PCT/JP2004/005280 JP2004005280W WO2004092206A1 WO 2004092206 A1 WO2004092206 A1 WO 2004092206A1 JP 2004005280 W JP2004005280 W JP 2004005280W WO 2004092206 A1 WO2004092206 A1 WO 2004092206A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- pro
- casein
- functional food
- chemotaxis
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 103
- 235000013376 functional food Nutrition 0.000 title claims description 23
- 238000000034 method Methods 0.000 title claims description 10
- 230000000091 immunopotentiator Effects 0.000 title 1
- 230000022275 macrophage chemotaxis Effects 0.000 claims abstract description 37
- 235000013305 food Nutrition 0.000 claims abstract description 32
- 102000011632 Caseins Human genes 0.000 claims abstract description 20
- 108010076119 Caseins Proteins 0.000 claims abstract description 20
- 102000038379 digestive enzymes Human genes 0.000 claims abstract description 18
- 108091007734 digestive enzymes Proteins 0.000 claims abstract description 18
- WRNQQFNBEUKAAX-YGQNSOCVSA-N beta-casochemotide-1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 WRNQQFNBEUKAAX-YGQNSOCVSA-N 0.000 claims abstract description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 16
- 230000001939 inductive effect Effects 0.000 claims abstract description 11
- 235000021247 β-casein Nutrition 0.000 claims abstract description 6
- 239000005018 casein Substances 0.000 claims description 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 14
- 235000021240 caseins Nutrition 0.000 claims description 13
- 230000003308 immunostimulating effect Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 229960001438 immunostimulant agent Drugs 0.000 claims description 6
- 239000003022 immunostimulating agent Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 17
- 108090000790 Enzymes Proteins 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 17
- 230000007123 defense Effects 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 5
- 102000014171 Milk Proteins Human genes 0.000 abstract description 4
- 108010011756 Milk Proteins Proteins 0.000 abstract description 4
- 235000021239 milk protein Nutrition 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 60
- 210000002540 macrophage Anatomy 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 29
- 230000035605 chemotaxis Effects 0.000 description 25
- 230000006870 function Effects 0.000 description 17
- 238000005259 measurement Methods 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 16
- 238000005194 fractionation Methods 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 210000005259 peripheral blood Anatomy 0.000 description 12
- 239000011886 peripheral blood Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000004365 Protease Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000000108 ultra-filtration Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 101710091342 Chemotactic peptide Proteins 0.000 description 9
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 239000012980 RPMI-1640 medium Substances 0.000 description 8
- 230000003399 chemotactic effect Effects 0.000 description 8
- 239000005482 chemotactic factor Substances 0.000 description 8
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000005571 anion exchange chromatography Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108090000526 Papain Proteins 0.000 description 6
- 108090000284 Pepsin A Proteins 0.000 description 6
- 102000057297 Pepsin A Human genes 0.000 description 6
- 235000019834 papain Nutrition 0.000 description 6
- 229940055729 papain Drugs 0.000 description 6
- 229940111202 pepsin Drugs 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000003185 calcium uptake Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000007857 degradation product Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 229920002494 Zein Polymers 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000007515 enzymatic degradation Effects 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 239000005019 zein Substances 0.000 description 4
- 229940093612 zein Drugs 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000002738 Giemsa staining Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229960002376 chymotrypsin Drugs 0.000 description 3
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- -1 tribcine Proteins 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 108090001109 Thermolysin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 2
- 238000003277 amino acid sequence analysis Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 101710180319 Protease 1 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000895740 Rattus norvegicus Alpha-S2-casein-like B Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
- PTPUOMXKXCCSEN-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-dichloro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(Cl)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(Cl)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O PTPUOMXKXCCSEN-UHFFFAOYSA-N 0.000 description 1
- AMJRSUWJSRKGNO-UHFFFAOYSA-N acetyloxymethyl 2-[n-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-5-(2,7-dichloro-3-hydroxy-6-oxoxanthen-9-yl)phenoxy]ethoxy]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O AMJRSUWJSRKGNO-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000001659 chemokinetic effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229960003339 sodium phosphate Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
- A23J3/343—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins
- A23J3/344—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins of casein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a novel peptide having an immunostimulating effect, a novel immunostimulant, a functional food, and a method for producing a functional food.
- the biggest enemy of healthy longevity is a group of diseases called "lifestyle-related diseases" such as cancer, stroke, 'heart disease', liver disease, kidney disease, and diabetes.
- lifestyle-related diseases such as cancer, stroke, 'heart disease', liver disease, kidney disease, and diabetes.
- lifestyle-related factors such as cancer, stroke, 'heart disease', liver disease, kidney disease, and diabetes.
- Milk protein is not only an excellent source of nitrogen and essential amino acids among the major food proteins, but also promotes bone formation and bone resorption by promoting the absorption of nutrients such as minerals and vitamins.
- a substance that has a regulating action that activates various functions of the living body such as a substance that has the effect of lowering blood cholesterol level, it is originally taken orally and works on the body in some way. It is designed.
- Non- Patent Documents 1 and 2 Since Brantle et al. Reported in 1979 that digests of milk casein had obioid agonist activity, peptides with various biological activities were separated and identified from casein digests (non- Patent Documents 1 and 2). Opioid peptides, which are typical peptides derived from milk proteins, have been suggested to be involved not only in analgesic action in the body but also in regulation of intestinal peristalsis and gastrointestinal function. (Non-Patent Document 3).
- angiotensin I converting enzyme inhibitory peptide that exerts hypotensive action immunoregulatory peptide that activates macrophage phagocytic activity and immunostimulatory action, platelet aggregation inhibitory peptide, ileal contractile peptide Etc.
- casein phosphopeptide which has calcium absorption promoting activity
- s1-casein which has antihypertensive activity
- milk casein is one of the factors that attracts attention.
- Non-Patent Document 4 Many substances have been reported to induce chemotaxis of macrophages (Non-Patent Document 4), but those whose chemotactic factor is identified as a peptide component are represented by fMLP. It is a bacterial formylated peptide, a peptide obtained from human peripheral blood lymphocytes (Patent Document 1), and a chemically synthesized peptide made from a peptide library (Non-Patent Document 5). Ovalbumin fragments obtained from egg white are only known as the origin (Patent Document 2).
- the present inventors aimed at providing a food that exerts a biological defense effect in the intestinal tract, and focused on the immunostimulatory ability of the milk protein component, and found that ⁇ -casein digestion was not achieved. Macrophage migration activity was found in the product, and the present invention was completed.
- the peptide of the present invention is a novel peptide comprising the following amino acid sequence shown in SEQ ID NO: 1.
- the immunostimulant of the present invention comprises, as an active ingredient, a peptide having the following amino acid sequence represented by SEQ ID NO: 1, and the use of the present invention comprises the following amino acid sequence represented by SEQ ID NO: 1 It is characterized in that the peptide is used as an immunostimulant.
- the functional food of the present invention is characterized in that it contains an amount of 31-potency zein digest that substantially exerts the ability to induce macrophage chemotaxis.
- the functional food of the present invention is characterized in that it contains an amount of a peptide having the following amino acid sequence represented by SEQ ID NO: 1 which substantially exerts the ability to induce macrophage chemotaxis. Tyr—Pro-Val-Glu—Pro
- the functional food of the present invention may be used in such an amount that the digestive enzyme in the living body produces a peptide having the following amino acid sequence represented by SEQ ID NO: 1 in an amount that substantially exerts the macrophage transit-inducing ability. It is characterized in that the ⁇ -casein 1118—119 residue bond in it is cleaved by digestive enzymes.
- the method for producing a functional food according to the present invention comprises a step of digesting ⁇ -potency zein in a food with a digestive enzyme so as to include an amount of a peptide that substantially exhibits macrophage chemotaxis-inducing ability. It is characterized by having. In this case, it is preferable to include a peptide having the following amino acid sequence represented by SEQ ID NO: 1.
- the method for producing a functional food of the present invention comprises the step of preparing a peptide having the following amino acid sequence represented by SEQ ID NO: 1 in an amount such that the in vivo digestive enzyme substantially exerts the ability to induce macrophage chemotaxis. It is characterized in that it has a step of cleaving the / 3_casein 118-119 residue bond in food with an enzyme to such an extent as to cause the occurrence.
- the method for producing a functional food of the present invention is characterized in that in the above-mentioned production method, actinase is used as a digestive enzyme.
- FIG. 1 is a photograph showing the PVPF membrane after Giemsa staining.
- FIG. 1A shows the entire PVPPF membrane, and
- FIG. B shows the migrated cells observed under a microscope.
- Figure 2 shows the induction of macrophage chemotaxis by various digestions of ⁇ _casein.
- FIG. 3 shows SDS polyacrylamide electrophoresis diagrams after various enzyme digestions of / 3-casein.
- Fig. A shows the electropherogram before enzymatic digestion
- Fig. B shows the digest (3 kD or less).
- FIG. 4 is a graph showing induction of macrophage-di-chemotaxis by fractions of various enzyme-digested ⁇ -casein having a molecular weight of 3 kD or less.
- FIG. 5 shows the induction of chemotaxis of human peripheral blood monocytes by fractionation of various enzymatic digestions—casein with a molecular weight of 3 kD or less
- Fig. 5A shows the purity of monosites by FACS CaliburTm
- FIG. 1B is a micrograph showing cells migrated by the digestion with actinase E
- FIG. 2C is a graph showing the number of cells migrated by the enzyme digest.
- FIG. 6 is a graph showing the time-dependent change of macrophage chemotaxis expressed by casein E digestion of casein.
- Figure 7 shows the fractionation of the macrophage chemotactic factor from the ⁇ -forced zine digest by anion exchange chromatography.
- the upper panel shows the UV absorption and the lower panel shows the chemotaxis. It is a figure by the number of induced cells.
- Fig. 8 shows the isolation and purification of macrophage chemotactic peptide by high performance liquid chromatography, and Fig. 8 shows the elution with 30% acetonitrile.
- the lower panel shows the elution of the Q fraction, and FIG. B shows the chemotaxis by the Q1, Q2, and Q3 fractions.
- FIG. 9 is a diagram of a checkerboard analysis of macrophage chemotactic peptide Q1.
- FIG. 10 shows the calcium mobilities of macrophage chemotactic peptide Q1, in which the upper row shows a laser microscopic image of macrophages incorporating Ca, and the lower row shows macrophages.
- FIG. 3 is a view showing a change in Ca uptake of phage.
- FIG. 11 is a diagram showing the concentration of calcium flowing in macrophages caused by stimulation of macrophage chemotactic peptide Q1.
- the present invention relates to a novel peptide that induces the chemotactic performance of macrophages.
- the novel peptide according to the present invention has a Tyr-Pro-Val-Glu-Pro amino acid sequence represented by SEQ ID NO: 1. (Hereinafter, the peptide is referred to as “/ 3-casochemotide”.)
- This peptide corresponds to residues / 3—casein 114-118, and was isolated and identified as an opioid peptide—neocazomorphin (SEQ ID NO: 2: Tyr-Pro-Val-Glu -Pro-Phe, 3-Casein (corresponding to residues 114 to 119) with the C-terminal (Phe) deleted.
- Power zokemotide is, for example, ⁇ -casein, various actinase (Ac hatase) typified by Actinase E (trade name, manufactured by Kaken Pharmaceutical Co., Ltd.).
- the peptide is obtained by treating with a proteinase such as Papain, and in particular, by treating with actinase, the peptide can be obtained at a high yield.
- This enzyme treatment does not require treatment under special conditions, and ordinary treatment conditions are selected. For example, optimum p H as shown in the following Table 1, Itaritekiba Ffa not limited by temperature optimum fi 1 erucic ⁇ under these conditions.
- the peptide can also be obtained by chemical synthesis.
- the functional food of the present invention includes a food with a health function (food for specified health use, a nutritional function food) and a food product advocating a physiological function, and has an amount of peptide that substantially exhibits macrophage chemotaxis-inducing ability. It contains.
- the functional food is obtained, for example, by adding a peptide according to the present invention isolated or synthesized from a protein digest of ⁇ -casein to an intended food.
- the enzymatic digest of ⁇ -casein may be added to the food as it is, so that the peptide contains an amount of peptide that substantially exerts macrophage chemotaxis-inducing ability during the food manufacturing process.
- ⁇ -casein may be digested using a protein digesting enzyme.
- raw milk is subjected to an enzyme treatment to produce a milk beverage, and raw milk subjected to the enzyme treatment is used as a raw material to produce milk products such as cheese and yogurt.
- the protein digesting enzyme used is not particularly limited as long as it produces the desired digest (peptide), but is preferably actinase.
- actinase AS for example, manufactured by Kaken Pharmaceutical Co., Ltd.
- actinase AS for example, manufactured by Kaken Pharmaceutical Co., Ltd.
- binds 118-119 residue bonds in ⁇ -casein contained in food You may cut it off.
- the 113-114 residue bond of ⁇ further further cut by indigenous digestive enzymes such as pepsin and trypsin.
- indigenous digestive enzymes such as pepsin and trypsin.
- the / 3-casein 113-114 residue bond in the food is cleaved in advance and the amount of macrophage chemotactic inducibility by the digestive enzymes in the body is substantially reduced.
- Peptides may be generated.
- the functional food of the present invention various foods can be considered in addition to the above-mentioned dairy products, and the kind and the like are not limited.
- the present invention is suitable for foods containing a large amount of casein and / or foods made from foodstuffs containing a large amount of / 3-force zein.
- the content of 8-casein is considered to be the amount that substantially exerts the ability to induce chemotacticity of macula phage, but the standard is about 0.01 to 10 mg per dose, preferably 0 It is about 1 to 5 mg.
- the same / 3-force zein was treated with the other six proteases (-chymotrypsin, pepsin, sa-molysin, tribcine, protease 1, no, o-no, o-in). Using.
- the enzyme digest obtained in the above (1) was subjected to ultrafiltration (3000 rpm, 4 ° C) with CENTRIPREP 3 (manufactured by Millipore) to obtain a fraction having a molecular weight of 3,000 or less.
- digested products of ⁇ -casein having a molecular weight of 300000 or less obtained in (2) above digested with enzyme E, Sep-Pak TM PlusC 18 sodium chloride (War) was used as a C18 reverse phase carrier. After adsorbing on 1Tm, ion-exchanged water, 3 Ov / v% acetonitrile, 60 v / v% acetonitrile, and 9 Ov / v% acetonitrile were passed through 1 Om 1 each, and the eluted fractions from each solution were passed through. Got. Thereafter, acetonitrile was removed by a centrifugal evaporator, lyophilized, and stored at -20 ° C.
- the 30 v / v% acetonitrile-eluted fraction obtained by the above (3) was subjected to mobile phase A (1 m 1) (solvent angle) using a Bio Logic chromatography system (manufactured by Biorad Laboratories, Inc.). The sample was subjected to ion exchange mouth chromatography under the following conditions.
- Mobile phase B (5OmM phosphate buffer pH 6.0 containing 1M NaC1) Elution: After holding for 8 minutes in mobile phase A, raise mobile phase B linearly to 50% in 5 minutes, Thereafter, the mobile phase B was raised to 100% in 4 minutes. Flow rate: 5.0ml / min
- Mobile phase B (60% acetonitrile containing 0.05v / v% TFA) Elution: After linearly increasing from 100% mobile phase A to 100% mobile phase B in 30 minutes, the mixture was kept in mobile phase B for 10 minutes.
- the peak obtained in this operation is collected, separated, and adsorbed on a Sep-pak TM Plus C18 cartridge, which is a C18 reverse phase carrier, according to the method (3) above, followed by ion exchange.
- TFA was removed by passing 1 Oml of water and 30% acetonitrile and collecting the eluted fraction of 30% acetonitrile. Furthermore, after removing acetonitrile by a centrifugal evaporator, the solution was freeze-dried and stored at 120 ° C.
- the gel after electrophoresis was electroplotted on Immobilon-PSQ (manufactured by Millipore), which is a PV DF membrane, using a plotting device SEMI-PH0R TM (manufactured by Hefa Chemical Chemical Instruments). That is, laying two filter papers soaked in Western buffer (2 OmM Tris base, 200 mMGlycin / dH 2 0) in blotting apparatus, pulled out completely bubble. After shaking with 100% methanol for 5 minutes, a PVDF membrane soaked in Western buffer was placed on top, and a separation gel was placed on top of it. Two pieces of filter paper soaked with Western buffer were placed on the gel to completely remove bubbles, and then plotted at 80 mA for 2 hours. The PVDF membrane on which the protein was transferred was stained by shaking with Quick I CBB (manufactured by Wako Pure Chemical Industries, Ltd.) for 5 minutes, and then the background was decolorized by shaking with 50% methanol. .
- Immobilon-PSQ
- a mouse-derived macrophage J774-1 strain (transferred from the Medical Cell Resource Center of the Tohoku University School of Medicine Aging Research Institute) was cultured in RPMI-1640 medium (containing 10% FCS) (manufactured by Sigma) for 10 passages. The experiment was used until the generation.
- Macrophage J774-1 was cultured in RPMI-1640 medium (containing 10% FCS) (manufactured by Sigma) and washed with RPMI-1640 complete medium (containing 1% BSA) at the time of attachment. were prepared 0 6 cells / m 1.
- Macrophage chemotaxis was measured according to the method previously reported by the present inventors (Int. J. Food Microbiol., 77, 29-38, (2002)). That is, the sample was diluted 2-fold with RPMI-1640 complete medium and placed in a lower well of a 48-well microchemotaxis chamber (manufactured by Europrobe) in 28 1 (triplicate). 25 x 80 thighs on this, 5.0 ⁇ 111? ⁇ After placing the PF membrane (manufactured by Neuroprobe), a rubber gasket and a lid were placed in this order, fastened with screws, and the macrophage suspension was dispensed in 50 1 portions into the upper well.
- the front side of PVPF film that is, the cells were seeded side was washed with PB S (manufactured by Okisoi de Co.), the cells in the filter wiper (manufactured by Neuro Probe Inc.)
- the PVPF membrane was stained with Giemsa using a wipe and a field staining solution (manufactured by Mutoh Chemical). Under microscope The number of macrophages that migrated at a magnification of 200 times was counted in 10 visual fields per sample, and the average number of migrated cells (high power field; HPF) was calculated.
- MiniMACS force ram (RS +, manufactured by Miltenyi Biotec GmbH) by magnetic cell separation system (hereinafter called “MACS”) (manufactured by Miltenyi Biotec GmbH) After cells (monocytes) was separated.
- the separated mode Nosaito is obtained by counting the number of viable cells was determined semi Ji Monosai Bok chemotaxis in the methods of the 3. macrophage chemotaxis test (2).
- the purity of human peripheral blood monosite isolated according to (1) above was determined by FACS Calibur TM flow. cytometer CFACS; manufactured by Becton Dickinson). That is, 1 ml of FACS washing buffer (2% FCS ⁇ 0.02% NaN 3 / PBS) was added to the monosites separated by MACS, washed by pipetting, and centrifuged (3200 rpm, 3 min ⁇ 4. The supernatant was removed by C). After repeating this operation three times, 10 ⁇ 1 of a biotin-labeled mouse anti-human CD11 bMAC-1 antibody (manufactured by Pharmingen) was added, and the mixture was reacted at 4 ° C. for 15 minutes in the dark.
- FACS washing buffer 2% FCS ⁇ 0.02% NaN 3 / PBS
- the chemotaxis of human peripheral blood monocytic cells was determined using ultrafiltration (1. Peptide preparation (2) above) as a test sample and the fraction obtained from RPMI_1640 complete medium (containing 1% BSA) at 1 mgZ '. Using a sample diluted to a concentration of m 1, measurement was carried out using a 48-well microchemotaxis chamber according to 3. Macrophage chemotaxis test (2) above.
- the macrophage chemotactic factor is a chemokinetic factor (activator induces cell movement at random, non-directional) or a chemotactic factor (directional) 9 Check as shown in the figure. Carbide analysis was performed. In other words, cells prepared by diluting the active peptide obtained in the above 1. Peptide preparation (5) to various concentrations are placed in the well below the Chemotaxis chamber, and the cells prepared using the chemotactic factor dilution in the upper well. The suspension was put. Next, the chemotaxis of macrophages was measured according to the above-mentioned macrophage chemotaxis test (2).
- Fluo-3AM (0.8 mM) dissolved in dimethylsulfoxide (DMSO, manufactured by Wako Pure Chemical Industries, Ltd.) was added in 5 z portions, and the solution was added at 5 ° C. 2 at 37 ° C. After incubation for 2 hours, the plate was washed twice with RPM1-1640 complete medium, and a drop was made again with RPMI-1640 complete medium.
- the Ca flux was measured using a laser microscope, and when the Fluo-3 AM intensity was stabilized, ionomycin, EGTA, fMLP or the above prepared in the same manner as in 10. Ca ion concentration measurement below. 1.
- the change in luminance was graphed by adding 5 ⁇ 1 to the active fraction obtained in peptide adjustment (5;).
- Macrophage suspension (1 ⁇ 10 6 cells / ml) 0.8 mM Fluo-3 in 1 ml
- A (manufactured by Molecular Probes) was added in an amount of 5 zl, and the mixture was incubated in a thermostat at 37 ° C for 30 minutes. After centrifugation (1500 rpm, 5 min, 4 ° C), remove the supernatant and remove 5% 1 ml of RPMI-1640 containing FCS was added and resuspended.
- Negative sample measurement The incubated cell suspension was set on a FACS, taken up for about 10 seconds, then removed, and lysed with RPMI-1640 at 6 mM: EGTA (Wako Pure Chemical Industries, Ltd.) (Manufactured by Co., Ltd.) was added in an amount of 500 ⁇ l, and quickly reset. During this work, data acquisition was continued.
- the number of migrating cells per visual field was counted using a light microscope at a magnification of 200 times.
- protease K As compared with the control, protease K :, actinase E, and the degradation products of They migrated about 6.8-fold, 4.3-fold, and 4.0-fold more, and a significant difference was observed (Fig. 2).
- C and S indicate the undigested enzyme and the digested enzyme, respectively.
- * Indicates that the difference was significant at the 5% significance level, and ** indicates that the difference was significant at the 1% significance level. means.
- the result is the average cell number in the HPF10 field.
- FIGS. 3B and 3A The results of subjecting this low molecular weight peptide and the peptide before ultrafiltration to SDS-PAGE are shown in FIGS. 3B and 3A, respectively.
- Figures 1 and 10 are molecular weights
- 2 is ⁇ -chymotrypsin digest
- 3 is pepsin digest
- 4 is thermolysin digest
- 5 is trypsin digest
- 6 is proteinase digestion.
- 7 shows the digest of actinase
- 8 shows the digest of papain
- 9 shows the undigested ⁇ -casein.
- the band of angle-forming peptides formed by ⁇ -chymotrypsin and trypsin was extremely reduced after ultrafiltration.
- no band of the peptide produced by degradation by actinase was detected before or after ultrafiltration.
- the macrophage chemotaxis was measured for fractions having a molecular weight of 300,000 or less of various enzymatically degraded peptides.
- the fractions degraded by proteases, actinase E, and papain were compared with the controls.
- the HPF values were about 5.5-fold, 5.8-fold and 5.1-fold, respectively, indicating a significant difference in the number of migrated macrophages (FIG. 4).
- Fig. 4 In the figure, * indicates that there was a significant difference at the 5% significance level. The result is the average cell number in the HPF 10 field.
- actinase E was an effective enzyme for inducing chemotactic peptides for both macrophages derived from mice and monosites derived from humans.
- the induction of chemotaxis in degraded peptides by actinase E was Changes over time were examined.
- a significant difference was observed in the number of migrating macrophages at 3 hours or more, about 1.6 times at 3 hours and 6 hours, about 2.5 times at 12 hours, and 2 times at 2 hours.
- At 4 hours about 3.5 times of macrophages migrated, and the chemotactic activity tended to increase with time. From these results, it was found that actinase E is preferable for the degradation of / 3-casein, and it is better to react at 37 ° C for 24 hours. In the following, tests were performed on digests obtained under these conditions.
- the molecular weights of Q1, Q2, and Q3 fractionated by high performance liquid chromatography were 604, 523, and 751, respectively.
- the array was obtained.
- the intracellular Ca 2t fluidity was measured with a laser microscope using a laser indicator ⁇ 1110-330 ⁇ .
- F MLP known as a potent chemotactic peptide
- Its activation mechanism in macrophages is that when a chemoattractant binds to its receptor, Ca ions are released from storage organs via inositol phosphate metabolism, and signaling activates adhesion factors such as MacI. It is thought that it will begin to run.
- chemotactic factors typified by chemokines exert their activity through G protein-related seven transmembrane receptors.
- the chemotactic peptide Q 1 is a concentration-dependent manner C a flux was observed, significant peak was obtained at 1 X 1 0- 3 M concentration (first 0 FIG lower left panel).
- the f MLP used as a control lower right figure in the figure. Therefore, when the intracellular Ca concentration was actually measured by tip-cytometry, the intracellular Ca concentration was found to be only about 6 2 At 0 nM, f MLP is about 170 nM, comparable to control, Supporting data from laser microscopy (Fig. 11), it is thought that / 3-force zokemotide may act on macrophages via a receptor different from f MLP.
- f MLP Ca 2+ fluidity
- ⁇ -casein may recognize the same receptor as fML ⁇ , but knowledge of its chemotactic peptide sequence and expression of chemotaxis through the receptor different from fMLP
- the peptide of the present invention is a novel inducer that enhances macrophage chemotaxis.
- the one-stroke zokemotide of the present invention is a pennin peptide (YPVEP) composed of five amino acids, its steric structure is difficult to change and its chemotaxis is also obtained by HPLC fractionation under high pressure. It can be easily separated without losing the inducibility.
- the bond between residues 113 (Lys) and 114 (Tyr) of ⁇ -peptide is cleaved with pepsin and trypsin, and the bond between 119 (Phe) and 120 (Thr) is It has been shown to be cleaved by chymotrypsin (Yunden Jinsmaa et al., Peputides, 20, 957-962 (1997)). Therefore, the peptide of the present invention, / 3-force zokemotide, is presumed to not undergo further enzymatic degradation because it is shorter, and can be sufficiently used for oral administration.
- the peptide is a novel peptide that induces macrophage motility and exhibits an immunostimulatory function.
- the 118-119 residue bond of / 3-casein is decomposed in advance with Actinase AS (for example, manufactured by Kaken Pharmaceutical Co., Ltd.) approved by the Ministry of Health, Labor and Welfare as a food additive.
- the peptide can also be produced by digestion of these ingested degradation products.
- the present invention provides a novel peptide that enhances macrophage chemotaxis.
- This peptide is highly safe because it is obtained by degrading ⁇ -casein contained in dairy products and other foods with evening digestive enzymes such as actinase E. Then, use the peptide directly or in the digestive tract.
- a new functional food utilizing an immunostimulatory function of a food-derived component is provided by pre-enzymatically treating the food as described above.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005505414A JP4476934B2 (ja) | 2003-04-14 | 2004-04-13 | 新規ペプチドおよび免疫賦活剤、機能性食品ならびに機能性食品の製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-109082 | 2003-04-14 | ||
JP2003109082 | 2003-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004092206A1 true WO2004092206A1 (ja) | 2004-10-28 |
Family
ID=33295908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/005280 WO2004092206A1 (ja) | 2003-04-14 | 2004-04-13 | 新規ペプチドおよび免疫賦活剤、機能性食品ならびに機能性食品の製造方法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4476934B2 (ja) |
WO (1) | WO2004092206A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010130956A1 (fr) * | 2009-05-13 | 2010-11-18 | Institut National De La Recherche Agronomique (Inra) | Peptides augmentant la secretion et/ou l ' expression d ' au moins une mucine gastro- intestinale et/ou induisant l ' augmentation de la population de cellules a mucus ou de cellules de paneth |
EP3595698A4 (en) * | 2017-03-16 | 2020-12-23 | Microsintesis Inc. | PROBIOTIC MOLECULES TO REDUCE THE VIRULENCE OF PATHOGENIC AGENTS |
US11857581B2 (en) | 2013-08-12 | 2024-01-02 | Microsintesis Inc. | Antiviral methods and compositions comprising probiotic bacterial molecules |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61112097A (ja) * | 1984-08-16 | 1986-05-30 | ロ−ン−プ−ラン・サント | 新規なトリペプチド類およびそれらの使用 |
JPH01160457A (ja) * | 1987-12-16 | 1989-06-23 | Snow Brand Milk Prod Co Ltd | ロイシン含量の高いペプチド混合物の製造方法 |
JPH08269090A (ja) * | 1995-03-28 | 1996-10-15 | Snow Brand Milk Prod Co Ltd | 新規ぺプチド |
WO2001011937A2 (en) * | 1999-08-17 | 2001-02-22 | The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines |
JP2003034638A (ja) * | 2001-06-28 | 2003-02-07 | Pfizer Prod Inc | アテローム性動脈硬化症の治療のための安息香酸置換ベンゾピラン |
WO2003102015A2 (en) * | 2002-05-29 | 2003-12-11 | University Of Florida | Method and apparatus for detecting and monitoring peptides, and peptides identified therewith |
-
2004
- 2004-04-13 JP JP2005505414A patent/JP4476934B2/ja not_active Expired - Lifetime
- 2004-04-13 WO PCT/JP2004/005280 patent/WO2004092206A1/ja active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61112097A (ja) * | 1984-08-16 | 1986-05-30 | ロ−ン−プ−ラン・サント | 新規なトリペプチド類およびそれらの使用 |
JPH01160457A (ja) * | 1987-12-16 | 1989-06-23 | Snow Brand Milk Prod Co Ltd | ロイシン含量の高いペプチド混合物の製造方法 |
JPH08269090A (ja) * | 1995-03-28 | 1996-10-15 | Snow Brand Milk Prod Co Ltd | 新規ぺプチド |
WO2001011937A2 (en) * | 1999-08-17 | 2001-02-22 | The University Of Texas System | Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines |
JP2003034638A (ja) * | 2001-06-28 | 2003-02-07 | Pfizer Prod Inc | アテローム性動脈硬化症の治療のための安息香酸置換ベンゾピラン |
WO2003102015A2 (en) * | 2002-05-29 | 2003-12-11 | University Of Florida | Method and apparatus for detecting and monitoring peptides, and peptides identified therewith |
Non-Patent Citations (6)
Title |
---|
ABUBAKAR A. ET AL: "Structural analysis of new antihypertensive peptides derived from cheese whey protein by proteinase K digestion", J DAIRY SCI, vol. 81, no. 12, 1998, pages 3131 - 3138, XP002937027 * |
JINSMAA Y ET AL: "Enzymatic release of neocasomorphin and beta-casomorphin from bovine beta-casein", PEPTIDES, vol. 20, no. 8, 1999, pages 957 - 962, XP002980615 * |
MIGLIORE-SAMOUR D. ET AL: "Biologically active casein peptides implicated in immunomodulation", J. OF DAIRY RESEARCH, vol. 56, no. 3, 1989, pages 357 - 362, XP002980613 * |
PARKER F. ET AL: "Immunostimulating hexapeptide from human casein: amino acid sequence, synthesis and biological properties", EUR. J. BIOCHEM., vol. 145, no. 3, 1984, pages 677 - 682, XP002980614 * |
PERPETUO EA ET AL: "Biochemical and pharmacological aspects of two bradykinin-potentiating peptides obtained from tryptic hydrolysis of casein", J PROEIN CHEM, vol. 22, no. 7-8, November 2003 (2003-11-01), pages 601 - 606, XP002980616 * |
ROBERT M-C ET AL: "Generation of bioactive peptides derived from caseins using a lactobacillus helveticus strain", PROCEEDINGS OF THE 2ND INT'L AND 17TH AMERICAN PEPTIDE SYMPOSIUM, PEPTIDES: THE WAVE OF THE FUTURE, 2001, pages 770 - 771, XP009030009 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010130956A1 (fr) * | 2009-05-13 | 2010-11-18 | Institut National De La Recherche Agronomique (Inra) | Peptides augmentant la secretion et/ou l ' expression d ' au moins une mucine gastro- intestinale et/ou induisant l ' augmentation de la population de cellules a mucus ou de cellules de paneth |
FR2945537A1 (fr) * | 2009-05-13 | 2010-11-19 | Agronomique Inst Nat Rech | Composes augmentant la secretion d'au moins une mucine gastro-intestinale. |
US11857581B2 (en) | 2013-08-12 | 2024-01-02 | Microsintesis Inc. | Antiviral methods and compositions comprising probiotic bacterial molecules |
EP3595698A4 (en) * | 2017-03-16 | 2020-12-23 | Microsintesis Inc. | PROBIOTIC MOLECULES TO REDUCE THE VIRULENCE OF PATHOGENIC AGENTS |
US11912788B2 (en) | 2017-03-16 | 2024-02-27 | Microsintesis Inc. | Probiotic molecules for reducing pathogen virulence |
Also Published As
Publication number | Publication date |
---|---|
JP4476934B2 (ja) | 2010-06-09 |
JPWO2004092206A1 (ja) | 2006-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kim et al. | Angiotensin I converting enzyme inhibitory peptides purified from bovine skin gelatin hydrolysate | |
Zambrowicz et al. | Manufacturing of peptides exhibiting biological activity | |
Megías et al. | Purification of an ACE inhibitory peptide after hydrolysis of sunflower (Helianthus annuus L.) protein isolates | |
Kamau et al. | Alpha‐lactalbumin: Its production technologies and bioactive peptides | |
KR101343904B1 (ko) | 우유 카제인의 효소 가수분해물에서 식별된 생물활성펩티드 및 그것을 얻는 방법 | |
CN107779489B (zh) | 一种具有抗氧化和ace抑制功能的蚕蛹蛋白肽 | |
CN109400678A (zh) | 一种刺参来源的抗氧化和dpp-iv抑制活性肽 | |
WO2005012542A1 (ja) | カゼイン加水分解物、その製造法及びその用途 | |
DK2995626T3 (en) | BIFUNCTIONAL FUSION PROTEINS TO INHIBIT ANGIOGENESIS IN TUMOR ENVIRONMENTS AND ACTIVATE ADAPTIVE IMMUNE RESPONSE, AND THE GENES AND APPLICATIONS THEREOF | |
JP2013516429A (ja) | ボーマン・バークインヒビタープロテインを大豆加工ストリームから回収する方法 | |
Chauhan et al. | Bioactive peptides: Synthesis, functions and biotechnological applications | |
CN108135961A (zh) | 调控免疫反应的方法及多肽 | |
Taniguchi et al. | Cationic peptides from peptic hydrolysates of rice endosperm protein exhibit antimicrobial, LPS-neutralizing, and angiogenic activities | |
CN103980354A (zh) | 真菌免疫调节蛋白FIP-ppl及其基因 | |
CN116063386B (zh) | 一种鹿角盘免疫活性肽及其制备方法和应用 | |
CN111269290B (zh) | 一种鲟鱼抗炎肽的制备方法 | |
CN111620932A (zh) | 一种多肽及在促进nk细胞增殖和提高其对肿瘤细胞杀伤力方面的应用 | |
CN111718399A (zh) | 一种多肽及用于nk细胞培养、制备nk细胞培养基的用途 | |
Kitazawa et al. | Enzymatic digestion of the milk protein β-casein releases potent chemotactic peptide (s) for monocytes and macrophages | |
WO2004092206A1 (ja) | 新規ペプチドおよび免疫賦活剤、機能性食品ならびに機能性食品の製造方法 | |
DK2300039T3 (en) | Anxiolytic composition comprising peptides derived from casein alphas1 | |
CN108250291A (zh) | 一种抗氧化骨胶原多肽及其制备方法 | |
KR20120049047A (ko) | 굴 가수분해물을 유효성분으로 함유하는 항염증 조성물 | |
KR20120079977A (ko) | 바지락 가수분해물을 유효성분으로 함유하는 항암제 조성물 | |
Salvado et al. | Enzymatic production of bioactive peptides from whey proteins: Their active role and potential health benefits |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005505414 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |